Kesselheim AS - Search Results

1

Transferable Exclusivity Vouchers and Incentives for Antimicrobial Development in the European Union.

Van de Wiele VL, Raymakers A, Kesselheim AS, Rome BN. Van de Wiele VL, et al. Among authors: kesselheim as. J Law Med Ethics. 2023;51(1):213-216. doi: 10.1017/jme.2023.58. Epub 2023 May 25. J Law Med Ethics. 2023. PMID: 37226746

2

Changes in the Number of Continuation Patents on Drugs Approved by the FDA.

Tu SS, Kesselheim AS, Wetherbee K, Feldman WB. Tu SS, et al. Among authors: kesselheim as. JAMA. 2023 Aug 1;330(5):469-470. doi: 10.1001/jama.2023.11525. JAMA. 2023. PMID: 37526728 Free PMC article.

3

FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012.

Rome BN, Kramer DB, Kesselheim AS. Rome BN, et al. Among authors: kesselheim as. JAMA. 2014 Jan 22-29;311(4):385-91. doi: 10.1001/jama.2013.284986. JAMA. 2014. PMID: 24449317 Free PMC article.

4

Approval of high-risk medical devices in the US: implications for clinical cardiology.

Rome BN, Kramer DB, Kesselheim AS. Rome BN, et al. Among authors: kesselheim as. Curr Cardiol Rep. 2014;16(6):489. doi: 10.1007/s11886-014-0489-0. Curr Cardiol Rep. 2014. PMID: 24760423 Free PMC article. Review.

5

Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.

Kesselheim AS, Rome BN, Sarpatwari A, Avorn J. Kesselheim AS, et al. Health Aff (Millwood). 2017 Feb 1;36(2):362-370. doi: 10.1377/hlthaff.2016.1340. Epub 2017 Jan 18. Health Aff (Millwood). 2017. PMID: 28100464

6

Defining "True and Non-Misleading" for Pharmaceutical Promotion.

Hey SP, Kesselheim AS. Hey SP, et al. Among authors: kesselheim as. J Law Med Ethics. 2018 Jun;46(2):552-554. doi: 10.1177/1073110518782970. J Law Med Ethics. 2018. PMID: 30146990 No abstract available.

7

The Tax Cuts and Jobs Act of 2017 and the Pharmaceutical Industry.

Sinha MS, Kesselheim AS. Sinha MS, et al. Among authors: kesselheim as. J Law Med Ethics. 2018 Sep;46(3):806-808. doi: 10.1177/1073110518804246. J Law Med Ethics. 2018. PMID: 30336090 No abstract available.

8

Approximating Future Generic Entry for New Drugs.

Beall RF, Darrow JJ, Kesselheim AS. Beall RF, et al. Among authors: kesselheim as. J Law Med Ethics. 2019 Mar;47(1):177-182. doi: 10.1177/1073110519840499. J Law Med Ethics. 2019. PMID: 30994060 No abstract available.

9

Orphan Drug Designation and Exclusivity for "Same Drugs".

Hong P, Sarpatwari A, Kesselheim AS. Hong P, et al. Among authors: kesselheim as. J Law Med Ethics. 2019 Jun;47(2):347-349. doi: 10.1177/1073110519857293. J Law Med Ethics. 2019. PMID: 31298092 No abstract available.

10

Lung Cancer Survival Gains: Contributions of Academia and Industry.

Gyawali B, Bouche G, Pantziarka P, Kesselheim AS, Sarpatwari A. Gyawali B, et al. Among authors: kesselheim as. J Law Med Ethics. 2019 Sep;47(3):465-467. doi: 10.1177/1073110519876182. J Law Med Ethics. 2019. PMID: 31560624 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

712 results

Search Page